134 related articles for article (PubMed ID: 38764824)
1. Chemoradiotherapy plus tislelizumab for mismatch repair proficient rectal cancer with supraclavicular lymph node metastasis: A case report.
Zhong WT; Lv Y; Wang QY; An R; Chen G; Du JF
World J Gastrointest Oncol; 2024 May; 16(5):2219-2224. PubMed ID: 38764824
[TBL] [Abstract][Full Text] [Related]
2. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
3. A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX.
Zhu J; Li G; Zhang Z; Wang Y
Immunotargets Ther; 2023; 12():17-23. PubMed ID: 36844460
[TBL] [Abstract][Full Text] [Related]
4. Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer.
Gao J; Zhang X; Yang Z; Zhang J; Bai Z; Deng W; Chen G; Xu R; Wei Q; Liu Y; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
Front Oncol; 2023; 13():1057947. PubMed ID: 36816939
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy.
Leibold T; Shia J; Ruo L; Minsky BD; Akhurst T; Gollub MJ; Ginsberg MS; Larson S; Riedel E; Wong WD; Guillem JG
J Clin Oncol; 2008 May; 26(13):2106-11. PubMed ID: 18362367
[TBL] [Abstract][Full Text] [Related]
6. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
7. Combined laparoscopic lymphoadenectomy of lateral pelvic and inguinal nodal metastases using indocyanine green fluorescence imaging guidance in low rectal cancer after preoperative chemoradiotherapy: a case report.
Sun Y; Lin Y; Liu Z; Jiang W; Chi P
BMC Gastroenterol; 2022 Mar; 22(1):123. PubMed ID: 35296259
[TBL] [Abstract][Full Text] [Related]
8. Cervical lymph node enlargement as the initial manifestation of rectal cancer.
Xie TH; Su P; Hong JG; Zhang H
BMC Gastroenterol; 2021 Feb; 21(1):57. PubMed ID: 33563207
[TBL] [Abstract][Full Text] [Related]
9. Successful resection of metachronous para-aortic, Virchow lymph node and liver metastatic recurrence of rectal cancer.
Takeshita N; Fukunaga T; Kimura M; Sugamoto Y; Tasaki K; Hoshino I; Ota T; Maruyama T; Tamachi T; Hosokawa T; Asai Y; Matsubara H
World J Gastroenterol; 2015 Nov; 21(44):12722-8. PubMed ID: 26640350
[TBL] [Abstract][Full Text] [Related]
10. Impact of the viability assessment of lateral lymph node metastasis in rectal cancer after neoadjuvant chemoradiotherapy.
Ozaki K; Kawai K; Nozawa H; Sasaki K; Murono K; Emoto S; Abe H; Ushiku T; Ishihara S
Int J Colorectal Dis; 2022 Feb; 37(2):467-473. PubMed ID: 35064299
[TBL] [Abstract][Full Text] [Related]
11. Complete remission in a patient with metastatic gastric cancer receiving tislelizumab combined with chemotherapy: a case report.
Zhu Z; Dai PL; Han S; Qiu E; Wang Y; Li Z
Front Oncol; 2023; 13():1147636. PubMed ID: 37234987
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Complete response after tislelizumab treatment in a hepatocellular carcinoma patient with abdominal lymph node metastasis.
Deng H; Chen B; Peng D; He J; Zhao W; Chen T; Xie Z; Pang F
Front Immunol; 2023; 14():1163656. PubMed ID: 37180122
[TBL] [Abstract][Full Text] [Related]
13. Virchow lymph node metastatic recurrence of sigmoid colon cancer with severe lymph node metastases successfully treated using systemic chemotherapy combined with radiotherapy.
Ohchi T; Akagi Y; Kinugasa T; Ishibashi Y; Tanaka N; Fujino S; Kibe S; Yuge K; Sasatomi T; Mizobe T; Oka Y; Hong KD; Shirouzu K
Anticancer Res; 2013 Jul; 33(7):2935-40. PubMed ID: 23780983
[TBL] [Abstract][Full Text] [Related]
14. [Risk factors related to lymph node metastases after neoadjuvant therapy for locally advanced rectal cancer].
Zeng ZF; Ding PR; Pan ZZ; Lin JZ; Li LR; Lu ZH; Wu XJ; Kong LH; Zhou ZG; Wan DS
Ai Zheng; 2009 Sep; 28(9):923-7. PubMed ID: 19728908
[TBL] [Abstract][Full Text] [Related]
15. Isolated synchronous Virchow lymph node metastasis of sigmoid cancer: A case report.
Yang JQ; Shang L; Li LP; Jing HY; Dong KD; Jiao J; Ye CS; Ren HC; Xu QF; Huang P; Liu J
World J Clin Cases; 2021 Nov; 9(32):9917-9925. PubMed ID: 34877331
[TBL] [Abstract][Full Text] [Related]
16. Effects of neoadjuvant chemotherapy plus chemoradiotherapy on lymph nodes in rectal adenocarcinoma.
Chotard G; Capdepont M; Denost Q; Smith D; Vendrely V; Rullier E; Rullier A
Virchows Arch; 2021 Oct; 479(4):657-666. PubMed ID: 33983519
[TBL] [Abstract][Full Text] [Related]
17. Pathological complete response in MMR-deficient/MSI-high and KRAS-mutant patient with locally advanced rectal cancer after neoadjuvant chemoradiation with immunotherapy: A case report.
Zhang M; Yang H; Chen L; Du K; Zhao L; Wei L
Front Oncol; 2022; 12():926480. PubMed ID: 36212424
[TBL] [Abstract][Full Text] [Related]
18. Is T classification still correlated with lymph node status after preoperative chemoradiotherapy for rectal cancer?
Kim DW; Kim DY; Kim TH; Jung KH; Chang HJ; Sohn DK; Lim SB; Choi HS; Jeong SY; Park JG
Cancer; 2006 Apr; 106(8):1694-700. PubMed ID: 16532432
[TBL] [Abstract][Full Text] [Related]
19. Optimal Size Criteria for Lateral Lymph Node Dissection After Neoadjuvant Chemoradiotherapy for Rectal Cancer.
Kawai K; Shiratori H; Hata K; Nozawa H; Tanaka T; Nishikawa T; Murono K; Ishihara S
Dis Colon Rectum; 2021 Mar; 64(3):274-283. PubMed ID: 33395141
[TBL] [Abstract][Full Text] [Related]
20. Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
Swellengrebel HA; Bosch SL; Cats A; Vincent AD; Dewit LG; Verwaal VJ; Nagtegaal ID; Marijnen CA
Radiother Oncol; 2014 Jul; 112(1):44-51. PubMed ID: 25018000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
